Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from ClearPoint Neuro ( (CLPT) ).
ClearPoint Neuro, Inc. has revised its Non-Employee Director Compensation Plan to attract and retain qualified board members by offering appropriate compensation. The updated plan, last revised on May 22, 2023, reflects the company’s commitment to strong corporate governance practices.
The most recent analyst rating on (CLPT) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on ClearPoint Neuro stock, see the CLPT Stock Forecast page.
Spark’s Take on CLPT Stock
According to Spark, TipRanks’ AI Analyst, CLPT is a Neutral.
ClearPoint Neuro’s overall stock score reflects its robust revenue growth and strategic initiatives, which are offset by ongoing profitability challenges and mixed technical indicators. The company’s solid financial backing and growth potential in the medical devices industry are key strengths, but the valuation remains a concern.
To see Spark’s full report on CLPT stock, click here.
More about ClearPoint Neuro
ClearPoint Neuro, Inc. operates in the medical technology industry, focusing on providing innovative solutions for neurosurgery. The company specializes in products and services that enhance precision and accuracy in neurological procedures.
Average Trading Volume: 281,240
Technical Sentiment Signal: Buy
Current Market Cap: $372.5M
Find detailed analytics on CLPT stock on TipRanks’ Stock Analysis page.